Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P35916
UPID:
VGFR3_HUMAN
Alternative names:
Fms-like tyrosine kinase 4; Tyrosine-protein kinase receptor FLT4
Alternative UPACC:
P35916; A8K6L4; B5A926; Q16067; Q86W07; Q86W08
Background:
Vascular endothelial growth factor receptor 3 (VEGFR-3), also known as Fms-like tyrosine kinase 4 (FLT4), plays a pivotal role in lymphangiogenesis and cardiovascular system development. It acts as a cell-surface receptor for VEGFC and VEGFD, promoting endothelial cell proliferation, survival, and migration. FLT4 signaling enhances VEGFC production, creating a feedback loop that amplifies its own signaling.
Therapeutic significance:
FLT4 is implicated in diseases such as Lymphatic malformation 1, characterized by lymphedema and hypoplasia of lymphatic vessels, and congenital heart defects. Understanding FLT4's role could lead to novel therapeutic strategies for these conditions, highlighting its importance in drug discovery.